Michail Ignatiadis, MD PhD is attending physician at the Medical Oncology Department, Jules Bordet Institute (IJB) and assistant professor at the Université Libre de Bruxelles, Brussels, Belgium. He has recently be appointed leader of the Academic Trials Promoting Team at the Jules Bordet Institut. His role is to stimulate and streamline the development of investigator-initiated trials across all tumour types and disciplines at the institutional level. He is also responsible for fund raising and for discussions with the pharmaceutical industry.
He is particularly interested in drug and biomarker development in breast cancer. His work in the field of blood-based biomarkers is widely recognised at the international level. He is principal investigator of the EORTC Treat CTC trial, the first trial using a liquid biopsy approach to improve the outcome of women with early breast cancer. He is member of the ASCO, ESMO, EORTC and AACR and treasurer of the EORTC Breast Cancer Group. He is in the editorial board of Scientific Reports and Annals of Oncology. He has published 70 articles in peer reviewed journals including several papers in high impact factor journals such as Journal of Clinical Oncology, Nature Reviews Clinical Oncology, Lancet Oncology as well as several book chapters; he is editor of a book on minimal residual disease.
He has served as reviewer for several national and international organisations including the French National Cancer Institute (INCA), the Technology Foundation STW in the Netherlands, the Marie-Curie Fellowships, the European Research Council (ERC) and the Innovative Medicines Initiative (IMI). He has served as Chair or Co-Chair of symposia in high visibility international conferences, organised by ESMO, ECCO and ASCO. He has been a faculty member in the prestigious workshop Methods in Clinical Cancer Research held in Flims (2014, 2015) and in Zeist (2016, 2017). He has obtained independent research funding over the last 2 years.